Comparison of prophylactic use of intravenous immunoglobulin versus Pentaglobin® in pediatric patients after hematopoietic stem cell transplantation
Fatih Azık
Department of Pediatric Hematology and Oncology, Ankara Children's Hematology and Oncology Hospital, Ankara, Turkey
Search for more papers by this authorCorresponding Author
Cengiz Bayram
Department of Pediatric Hematology and Oncology, Ankara Children's Hematology and Oncology Hospital, Ankara, Turkey
Cengiz Bayram, Department of Pediatric Hematology and Oncology, Ankara Children's Hematology and Oncology Hospital, Ankara 06110, Turkey
Tel.: +90 505 839 6092
Fax: +90 312 347 2330
E-mail: [email protected]
Search for more papers by this authorMustafa Erkoçoğlu
Department of Pediatric Allergy and Immunology, Ankara Children's Hematology and Oncology Hospital, Ankara, Turkey
Search for more papers by this authorHasan Tezer
Department of Pediatric Infectious Diseases, Ankara Children's Hematology and Oncology Hospital, Ankara, Turkey
Search for more papers by this authorArzu Yazal Erdem
Department of Pediatric Hematology and Oncology, Ankara Children's Hematology and Oncology Hospital, Ankara, Turkey
Search for more papers by this authorPamir Işık
Department of Pediatric Hematology and Oncology, Ankara Children's Hematology and Oncology Hospital, Ankara, Turkey
Search for more papers by this authorZekai Avcı
Department of Pediatric Hematology and Oncology, Ankara Children's Hematology and Oncology Hospital, Ankara, Turkey
Search for more papers by this authorNamık Özbek
Department of Pediatric Hematology and Oncology, Ankara Children's Hematology and Oncology Hospital, Ankara, Turkey
Search for more papers by this authorBetül Tavil
Department of Pediatric Hematology and Oncology, Ankara Children's Hematology and Oncology Hospital, Ankara, Turkey
Search for more papers by this authorBahattin Tunc
Department of Pediatric Hematology and Oncology, Ankara Children's Hematology and Oncology Hospital, Ankara, Turkey
Search for more papers by this authorFatih Azık
Department of Pediatric Hematology and Oncology, Ankara Children's Hematology and Oncology Hospital, Ankara, Turkey
Search for more papers by this authorCorresponding Author
Cengiz Bayram
Department of Pediatric Hematology and Oncology, Ankara Children's Hematology and Oncology Hospital, Ankara, Turkey
Cengiz Bayram, Department of Pediatric Hematology and Oncology, Ankara Children's Hematology and Oncology Hospital, Ankara 06110, Turkey
Tel.: +90 505 839 6092
Fax: +90 312 347 2330
E-mail: [email protected]
Search for more papers by this authorMustafa Erkoçoğlu
Department of Pediatric Allergy and Immunology, Ankara Children's Hematology and Oncology Hospital, Ankara, Turkey
Search for more papers by this authorHasan Tezer
Department of Pediatric Infectious Diseases, Ankara Children's Hematology and Oncology Hospital, Ankara, Turkey
Search for more papers by this authorArzu Yazal Erdem
Department of Pediatric Hematology and Oncology, Ankara Children's Hematology and Oncology Hospital, Ankara, Turkey
Search for more papers by this authorPamir Işık
Department of Pediatric Hematology and Oncology, Ankara Children's Hematology and Oncology Hospital, Ankara, Turkey
Search for more papers by this authorZekai Avcı
Department of Pediatric Hematology and Oncology, Ankara Children's Hematology and Oncology Hospital, Ankara, Turkey
Search for more papers by this authorNamık Özbek
Department of Pediatric Hematology and Oncology, Ankara Children's Hematology and Oncology Hospital, Ankara, Turkey
Search for more papers by this authorBetül Tavil
Department of Pediatric Hematology and Oncology, Ankara Children's Hematology and Oncology Hospital, Ankara, Turkey
Search for more papers by this authorBahattin Tunc
Department of Pediatric Hematology and Oncology, Ankara Children's Hematology and Oncology Hospital, Ankara, Turkey
Search for more papers by this authorAbstract
There are few studies evaluating the use of IgM-enriched IVIG (Pentaglobin®) in HSCT recipients. This study aimed to compare the efficacy of prophylactic use of IVIG versus prophylactic use of Pentaglobin® within the first 100 days after allogeneic HSCT. We performed a prospective, randomized study of the use of prophylactic IVIG versus prophylactic use of Pentaglobin® in patients after allogeneic HSCT. The first dose of IVIG or Pentaglobin® was given before conditioning regimen and after transplant was given on day +1, +8, +15, and +22. And then, it was given if IgG level was below 400 mg/dL. Twenty-seven patients in IVIG group and 32 patients in Pentaglobin® group were included in the study. There were no significant differences in the duration of neutropenia, hospitalization, fever, and in the number of pyrexial episode, septicemia, bacteremia, local infection, CMV infection, acute GVHD, VOD, and adverse events between the IVIG group and Pentaglobin® group. Randomized placebo-controlled trials are needed to conclude that utilization of IVIG or Pentaglobin® has no beneficial effect in HSCT.
References
- 1Siadak MF, Kopecky K, Sullivan KM. Reduction in transplant-related complications in patients given intravenous immuno globulin after allogeneic marrow transplantation. Clin Exp Immunol 1994: 97(Suppl 1): 53–57.
- 2Norlin AC, Sairafi D, Mattsson J, Ljungman P, Ringdén O, Remberger M. Allogeneic stem cell transplantation: Low immunoglobulin levels associated with decreased survival. Bone Marrow Transplant 2008: 41: 267–273.
- 3Sullivan KM, Kopecky KJ, Jocom J, et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 1990: 323: 705–712.
- 4Akhan H, Cordonnier C. Antimicrobial prophylaxis in EBMT centers: A report from the EBMT Infectious Diseases Working Party (abstract). Bone Marrow Transplant 2001: 27(Suppl 1): S202.
- 5Winston DJ, Antin JH, Wolff SN, et al. A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation. Bone Marrow Transplant 2001: 28: 187–196.
- 6Schmidt-Hieber M, Schwarck S, Stroux A, et al. Prophylactic i.v. Igs in patients with a high risk for CMV after allo-SCT. Bone Marrow Transplant 2009: 44: 185–192.
- 7Norrby-Teglund A, Haque KN, Hammarström L. Intravenous polyclonal IgM-enriched immunoglobulin therapy in sepsis: A review of clinical efficacy in relation to microbiological aetiology and severity of sepsis. Review. J Intern Med 2006: 260: 509–516.
- 8Schedel I, Dreikhausen U, Nentwig B, et al. Treatment of gram-negative septic shock with an immunoglobulin preparation: A prospective, randomized clinical trial. Crit Care Med 1991: 19: 1004–1013.
- 9Rodríguez A, Rello J, Neira J, et al. Effects of high-dose of intravenous immunoglobulin and antibiotics on survival for severe sepsis undergoing surgery. Shock 2005: 23: 298–304.
- 10Kreymann KG, de Heer G, Nierhaus A, Kluge S. Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med 2007: 35: 2677–2685.
- 11Alejandria MM, Lansang MA, Dans LF, Mantaring JB III. Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database Syst Rev 2013: 9: CD001090.
- 12Capasso L, Borrelli AC, Parrella C, et al. Are IgM-enriched immunoglobulins an effective adjuvant in septic VLBW infants? Ital J Pediatr 2013: 39: 63.
- 13Garbett ND, Munro CS, Cole PJ. Opsonic activity of a new intravenous immunoglobulin preparation: Pentaglobin compared with sandoglobulin. Clin Exp Immunol 1989: 76: 8–12.
- 14McCabe WR, DeMaria AJ. Immunization with rough mutants of Salmonella minnesota: Protective activity of IgM and IgG antibody to the R595 (Re chemotype) mutant. J Infect Dis 1988: 158: 291–300.
- 15Trautmann M, Held TK, Susa M, et al. Bacterial lipopolysaccharide (LPS)-specific antibodies in commercial human immunoglobulin preparations: Superior antibody content of an IgM-enriched product. Clin Exp Immunol 1998: 111: 81–90.
- 16Poynton CH, Jackson S, Fegan C, Barnes RA, Whittaker JA. Use of IgM enriched intravenous immunoglobulin (Pentaglobin) in bone marrow transplantation. Bone Marrow Transplant 1992: 9: 451–457.
- 17Jackson SK, Parton J, Barnes RA, Poynton CH, Fegan C. Effect of IgM-enriched intravenous immunoglobulin (Pentaglobin) on endotoxaemia and anti-endotoxin antibodies in bone marrow transplantation. Eur J Clin Invest 1993: 23: 540.
- 18McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED. Venocclusive disease of the liver after bone marrow transplantation: Diagnosis, incidence, and predisposing factors. Hepatology 1984: 4: 116–122.
- 19Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974: 18: 295–304.
- 20Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995: 15: 825–828.
- 21De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008: 46: 1813–1821.
- 22Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002: 34: 1094–1097.
- 23Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011: 52: e56–e93.
- 24Winston DJ, Ho WG, Lin CH, et al. Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann Intern Med 1987: 106: 12–18.
- 25Bass EB, Powe NR, Goodman SN, et al. Efficacy of immune globulin in preventing complications of bone marrow transplantation: A meta-analysis. Bone Marrow Transplant 1993: 12: 273–282.
- 26Glowacki LS, Smaill FM. Meta-analysis of immune globulin prophylaxis in transplant recipients for the prevention of symptomatic cytomegalovirus disease. Transplant Proc 1993: 25(Pt 2): 1408–1410.
- 27Cordonnier C, Chevret S, Legrand M, et al. Should immunoglobulin therapy be used in allogeneic stem-cell transplantation? A randomized, double-blind, dose effect, placebo-controlled, multicenter trial. Ann Intern Med 2003: 139: 8–18.
- 28Raanani P, Gafter-Gvili A, Paul M, Ben-Bassat I, Leibovici L, Shpilberg O. Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: Systematic review and meta-analysis. J Clin Oncol 2009: 27: 770–781.
- 29Howell JE, Gulbis AM, Champlin RE, Qazilbash MH. Retrospective analysis of weekly intravenous immunoglobulin prophylaxis versus intravenous immunoglobulin by IgG level monitoring in hematopoietic stem cell transplant recipients. Am J Hematol 2012: 87: 172–174.
- 30Sheridan JF, Tutschka PJ, Sedmak DD, Copelan EA. Immunoglobulin G subclass deficiency and pneumococcal infection after allogeneic bone marrow transplantation. Blood 1990: 75: 1583–1586.
- 31Sullivan KM, Storek J, Kopecky KJ, et al. A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: Clinical outcome and effect on subsequent immune recovery. Biol Blood Marrow Transplant 1996: 2: 44–53.
- 32Feinstein LC, Seidel K, Jocum J, et al. Reduced dose intravenous immunoglobulin does not decrease transplant-related complications in adults given related donor marrow allografts. Biol Blood Marrow Transplant 1999: 5: 369–378.
- 33Frangoul H, Min E, Wang W, et al. Incidence and risk factors for hypogammaglobulinemia in pediatric patients following allo-SCT. Bone Marrow Transplant 2013: 48: 1456–1459.
- 34Sundin M, Remberger M, Lindqvist H, et al. Hypogammaglobulinemia in children after allogeneic hematopoietic stem cell transplantation: A cytokine mediated immunoglobulin isotype class switch arrest? Pediatr Blood Cancer 2015: 62: 890–896.
- 35 Centers for Disease Control and Prevention; Infectious Disease Society of America; American Society of Blood and Marrow Transplantation. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep 2000: 49: 1–125, CE121–CE127.
- 36Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: A global perspective. Bone Marrow Transplant 2009: 44: 453–558.
- 37Wolff SN, Fay JW, Herzig RH, et al. High-dose weekly intravenous immunoglobulin to prevent infections in patients undergoing autologous bone marrow transplantation or severe myelosuppressive therapy. A study of the American Bone Marrow Transplant Group. Ann Intern Med 1993: 118: 937–942.
- 38Klaesson S, Ringdén O, Ljungman P, Aschan J, Hägglund H, Winiarski J. Does high-dose intravenous immune globulin treatment after bone marrow transplantation increase mortality in veno-occlusive disease of the liver? Transplantation 1995: 60: 1225–1230.
Citing Literature
